Search

Displaying results 2101 - 2110 of 9314 in total
  1. Drug

    Buclizine

    go.drugbank.com/drugs/DB00354
    Approved

    [A178102] In addition to the above conditions, buclizine has been studied in the treatment of migraine attacks and in the treatment of nausea and vomiting during pregnancy. [A178105, A178108] … [L6217] Following this, it was touted to be effective as an appetite stimulant in children when administered in the syrup form, however, this indication has not been validated.

  2. Drug

    Dornase alfa

    go.drugbank.com/drugs/DB00003
    ApprovedInvestigational

    The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. … Enzymatic breakdown of this extracellular DNA appears to reduce sputum viscosity and viscoelasticity.

    Products: PULMOZYME 2.500 E./2,5 ml - Lösung für einen Vernebler
  3. Drug

    Deoxycholic acid

    go.drugbank.com/drugs/DB03619
    ApprovedInvestigational

    In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity. … It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical

  4. Drug

    Neostigmine

    go.drugbank.com/drugs/DB01400
    ApprovedInvestigationalVet approved

    A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. … Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.

    Products: NEOSTIGMINA METILSULFATO SOLUCION INYECTABLE DE 0.5 MG / 1 ML.
  5. Drug

    Adagrasib

    go.drugbank.com/drugs/DB15568
    ApprovedInvestigational

    [A254941] However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate (GDP), as well as the lack of a clear binding … [L43847] In December 2022, the FDA granted accelerated approval to adagrasib for the treatment of KRAS<sup>G12C</sup>-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic

  6. Drug

    Probucol

    go.drugbank.com/drugs/DB01599
    ApprovedInvestigationalWithdrawn

    A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).

  7. Drug

    Durlobactam

    go.drugbank.com/drugs/DB16704
    ApprovedInvestigational

    [L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023. … It is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases.

  8. Drug

    Propanoic acid

    go.drugbank.com/drugs/DB03766
    ApprovedInvestigationalVet approvedWithdrawn

    Sodium propionate was previously approved in Canada as an active ingredient in Amino-Cerv (used to treat inflammation or injury of the cervix). … Sodium propionate is the sodium salt of propionic acid that exists as colorless, transparent crystals or a granular crystalline powder.

  9. Drug

    Sacituzumab govitecan

    go.drugbank.com/drugs/DB12893
    ApprovedInvestigational

    approval for the treatment of mTNBC patients who have undergone two or more prior therapies. … As a targeted cytotoxic agent, it is hoped to provide similar efficacy with reduced adverse effects.

  10. Drug

    Rofecoxib

    go.drugbank.com/drugs/DB00533
    ApprovedWithdrawn

    Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. … This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety.